A Jewish Legal Perspective on Gene Editing
In a groundbreaking medical achievement, a 57-year-old patient received a heart transplant in January 2022 that would have been unimaginable just decades earlier. The donor wasn't human—it was a pig, genetically modified using CRISPR technology to make its organs compatible with human biology 1 . This remarkable milestone represents just one of the countless ways clustered regularly interspaced short palindromic repeats (CRISPR) is revolutionizing medicine and science.
For Jewish legal scholars, these modern dilemmas connect to ancient conversations about humanity's role in creation. The Jewish tradition presents a nuanced perspective that generally embraces scientific progress while establishing important ethical boundaries. As CRISPR technology advances at a breathtaking pace—progressing from laboratory curiosity to clinical application in under a decade—Jewish law (halakhah) provides a comprehensive framework for evaluating these developments that balances innovation with responsibility 1 2 .
CRISPR technology represents one of the most significant breakthroughs in genetic engineering, allowing precise editing of DNA sequences.
Jewish law provides a structured approach to evaluating new technologies, balancing innovation with moral responsibility.
CRISPR didn't originate in high-tech laboratories but in the humblest of places: bacteria. For billions of years, bacteria have been developing immune systems to protect themselves from invading viruses. They capture snippets of viral DNA and store them in special regions of their own genome called clustered regularly interspaced short palindromic repeats (CRISPR) 9 .
When the same virus attacks again, the bacteria produce RNA molecules that act like "most wanted posters" to identify the enemy. These guide RNAs partner with CRISPR-associated (Cas) proteins—molecular scissors that cut and disable the viral DNA 1 . This bacterial defense system functions similarly to human adaptive immunity, creating a genetic memory of past invaders for faster future response 9 .
CRISPR sequences first discovered in bacteria
Researchers recognize CRISPR as a bacterial immune system
Charpentier and Doudna develop CRISPR-Cas9 for gene editing
Nobel Prize in Chemistry awarded for CRISPR discovery
First FDA-approved CRISPR therapy (Casgevy)
CRISPR introduces cuts that disrupt gene function
Cells repair mutations using provided DNA templates
Turning genes on or off without cutting DNA
Changing individual DNA letters with precision
This versatility makes CRISPR uniquely accessible and powerful compared to previous gene-editing technologies. As Dr. Stanley Qi notes, "CRISPR dramatically reduces the burdens, cost, timing, while increasing the precision and accuracy of a gene-editing system" 9 .
Jewish tradition provides a compelling philosophical foundation for considering humanity's role in manipulating nature. Unlike some ethical frameworks that view genetic engineering as inherently problematic "playing God," Jewish law generally sees scientific innovation as fulfilling a divine mandate.
The Bible states that God created humans in His image and commanded them to "replenish the earth and subdue it and have dominion over the fish of the seas and over the birds of the air and over every living thing that moves on the earth" 5 . Nachmanides, the twelfth-century commentator, explained that this passage grants humans "the ability and the rulership over the earth to do according to man's will with animals, plants, and inanimate matter" 5 .
God created the cures for all diseases even before He created disease pathology.
This theme of human partnership in creation appears vividly in a midrashic story where Rabbi Akiva defends circumcision to a Roman critic named Turnus Rufus. When challenged about why humans would alter God's creation, Rabbi Akiva brought out kernels of wheat and loaves of bread, asking which was more perfect. The Roman naturally chose the bread—the transformed product of human effort applied to natural materials. Rabbi Akiva demonstrated that God intentionally created an unfinished world so that humans could partner in its perfection 5 .
This perspective doesn't give humans carte blanche to do whatever they wish with creation. The same tradition that grants authority also imposes limits. Another midrash recounts that when God created the first human, "He took him and showed him all the trees of the Garden of Eden and said to him 'See my works, how beautiful and praiseworthy they are. And everything that I created, I created it for you. Be careful not to spoil or destroy my world—for if you do, there will be nobody after you to repair it'" 5 .
This balance between innovation and restraint frames the Jewish approach to CRISPR technology. The fundamental question becomes not whether we can manipulate genes, but whether our manipulations heal and improve or damage and destroy.
Jewish law places supreme importance on pikuakh nefesh—the preservation of human life—which overrides virtually all other religious considerations 5 . From this perspective, using CRISPR to treat or prevent disease isn't just permitted—it may be morally required.
This principle clearly sanctions using CRISPR to address the approximately 7,000-10,000 genetic diseases caused by specific mutations, such as cystic fibrosis, Tay-Sachs disease, or Duchenne muscular dystrophy 1 . The Talmud states that "God created the cures for all diseases even before He created disease pathology" 2 , suggesting that discovering and applying medical treatments fulfills divine intention rather than contradicts it.
Two areas of Jewish law particularly relevant to CRISPR applications that transfer genetic material between species are kashrut (dietary laws) and kilayim (prohibitions against mixing species).
When genetic material from non-kosher animals is introduced into kosher species, does this render the recipient non-kosher? Most rabbinic authorities consider separated genetic material to be "inert" and not constitutive of the donor organism's essential character. Rabbi Eliyahu Bakshi-Doron, former Chief Sephardic Rabbi of Israel, notes that transferred genetic material typically isn't considered "food," has no taste, and is negligible in quantity compared to the host—all factors suggesting it wouldn't affect kosher status 5 .
| Application Category | General Jewish Legal Position | Key Considerations |
|---|---|---|
| Medical Applications | Permitted and potentially required | Preservation of life (pikuakh nefesh) is paramount; distinction between somatic and germline editing |
| Genetic Transfer Between Animal Species | Generally permitted | Most authorities consider genetic material "inert"; kilayim prohibition typically applies only to sexual interbreeding |
| Plant Genetic Engineering | Mostly permitted | Some debate depending on whether transferred material could grow independently |
| Kosher Status Modifications | Complex case-by-case determination | Changes to physical characteristics used for kosher identification require careful analysis |
In 2019, Victoria Gray became the first person in the United States to receive CRISPR treatment for sickle cell anemia, a genetic blood disorder that causes severe pain, organ damage, and reduced lifespan 9 . The successful treatment represented a milestone in genetic medicine and offers a compelling case study for examining CRISPR through a Jewish legal lens.
Sickle cell anemia results from a single mutation in the gene encoding adult hemoglobin, causing red blood cells to deform into sickle shapes that block blood vessels 1 . Interestingly, patients with this mutation don't experience symptoms until after birth because they produce fetal hemoglobin during embryonic development. After birth, a "switch" turns off the fetal hemoglobin gene and turns on the adult version—including the sickle cell mutation 1 .
Researchers realized they could use CRISPR to reactivate fetal hemoglobin production by targeting this genetic "switch." The approach doesn't fix the mutated adult hemoglobin gene but instead addresses the condition by enabling continued production of the functioning fetal form 1 .
Chart: Patient outcomes after CRISPR treatment
| Step | Procedure | Purpose | Considerations |
|---|---|---|---|
| 1. Cell Collection | Harvest blood-forming stem cells from patient's bone marrow | Obtain cells for genetic modification | Avoids ethical issues of embryo editing; uses patient's own cells |
| 2. CRISPR Editing | Use CRISPR-Cas9 to cut DNA control region disrupting fetal hemoglobin "off switch" | Reactivate production of functioning fetal hemoglobin | High precision required; off-target effects must be minimized |
| 3. Cell Validation | Multiply edited cells and test for successful genetic modification | Ensure treatment will be effective before reintroduction | Quality control step crucial for patient safety |
| 4. Preparation | Administer chemotherapy to clear existing bone marrow | Make space for edited cells to engraft | Most medically risky step of the procedure |
| 5. Reinfusion | Introduce edited cells back into patient's bloodstream | Establish population of corrected cells in bone marrow | Edited cells naturally migrate to appropriate locations |
This application of CRISPR presents a relatively straightforward case from a Jewish legal perspective. The treatment clearly preserves and prolongs human life, addresses a serious genetic disease, uses the patient's own cells, and offers benefits that outweigh the risks. As such, this application would not only be permitted under Jewish law but would likely be encouraged as fulfilling the commandment to preserve life.
CRISPR research requires specific molecular tools and delivery systems. The table below outlines key components used in CRISPR experiments, particularly those relevant to therapeutic applications like the sickle cell treatment.
| Component | Function | Therapeutic Considerations |
|---|---|---|
| Cas Enzymes | Molecular scissors that cut DNA at specific locations; Cas9 is most common | High-fidelity versions increase specificity; different Cas variants have different PAM requirements |
| Guide RNA (gRNA) | RNA molecule that directs Cas enzyme to target DNA sequence; combines crRNA and tracrRNA | Design crucial for minimizing off-target effects; bioinformatics tools help predict optimal sequences |
| Delivery Vectors | Methods to introduce CRISPR components into cells; includes plasmids, viral vectors, and ribonucleoproteins | Lentiviral and AAV vectors common for therapeutics; each has different packaging capacity and safety profile |
| Repair Templates | DNA templates provided to guide cellular repair mechanisms for precise edits (HDR) | Required for specific mutations; efficiency lower than error-prone NHEJ repair |
| Cell Lines | Specific cell types used for experimentation or therapy | Hematopoietic stem cells used for blood disorders; other cell types require different optimization |
The selection of appropriate CRISPR components depends on the specific experimental or therapeutic goals. For gene knockouts, standard Cas9 and a single guide RNA may suffice. For precise edits, additional elements like repair templates or specialized base editors may be required 6 .
Delivery methods vary based on the target cells. The sickle cell therapy used ex vivo approach—cells were edited outside the body then returned—which offers greater control and safety. For other conditions, in vivo delivery (editing cells inside the body) may be necessary, requiring different vector systems 6 .
Chart: CRISPR applications across different cell types
As CRISPR technology continues to advance at a remarkable pace, Jewish legal scholars face new questions that lack clear precedents. The first pig-to-human heart transplant in 2022, made possible by CRISPR edits to pig genes, represents just one of many emerging applications 1 . Researchers used CRISPR to modify at least ten pig genes to make the organs less likely to be rejected by the human immune system 1 .
Using CRISPR to engineer bacteriophages to target antibiotic-resistant bacterial infections 1 .
Creating genetically modified mosquitoes that pass on infertility genes to reduce populations of malaria-carrying insects 1 .
Modifying animal organs to make them suitable for human transplantation to address the critical shortage of donor organs 1 .
Altering the chemistry of DNA without changing its sequence to regulate gene expression 9 .
Each of these applications raises unique ethical considerations that Jewish law must address. For example, gene drive technology could save millions from malaria but might irreversibly alter ecosystems. Xenotransplantation could eliminate transplant waiting lists but raises concerns about mixing species boundaries.
Jewish legal analysis typically addresses such questions at two levels: first, a general theoretical analysis of legal history and principles; second, a practical approach that examines each situation according to its specific circumstances and details 2 . This case-by-case methodology allows for nuanced consideration of both the potential benefits and risks of each application.
The general principle in Judaism is that gene editing for non-medical applications—such as cosmetic enhancements, sex selection, or creating "designer babies" with selected traits—is ethically problematic and "should not be routinely acceptable" 2 .
CRISPR technology represents one of the most transformative developments in human history, granting us unprecedented power to reshape life itself. As we navigate this new territory, the Jewish legal tradition offers a time-tested framework for balancing innovation with responsibility, progress with precaution.
The Jewish perspective generally embraces CRISPR as a tool for healing and improving life—a modern manifestation of humanity's ancient role as partner in creation. As the Talmud observes, the answers to curing human diseases lie within natural laws that God created before creating disease itself 2 . From this viewpoint, CRISPR represents not a violation of divine boundaries but a fulfillment of human potential.
"Be careful not to spoil or destroy my world—for if you do, there will be nobody after you to repair it." 5
References will be added here in the proper format.